Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 376,866,944
  • Shares Outstanding, K 2,682,900
  • Annual Sales, $ 76,450 M
  • Annual Income, $ 1,300 M
  • 36-Month Beta 0.69
  • Price/Sales 5.01
  • Price/Cash Flow 14.95
  • Price/Book 6.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 2.03
  • Number of Estimates 8
  • High Estimate 2.09
  • Low Estimate 2.00
  • Prior Year 1.90
  • Growth Rate Est. (year over year) +6.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
133.44 +3.90%
on 09/04/18
143.13 -3.14%
on 09/21/18
+2.69 (+1.98%)
since 08/24/18
3-Month
120.11 +15.43%
on 07/02/18
143.13 -3.14%
on 09/21/18
+16.05 (+13.09%)
since 06/25/18
52-Week
118.62 +16.88%
on 05/29/18
148.32 -6.53%
on 01/17/18
+7.47 (+5.69%)
since 09/25/17

Most Recent Stories

More News
Markets Right Now: Stocks close mostly lower on Wall Street

NEW YORK (AP) — The latest on developments in financial markets (all times local):

CVX : 123.37 (+0.61%)
COP : 78.11 (+1.36%)
JNJ : 138.64 (-1.30%)
Top Research Reports for Johnson & Johnson, Visa & Verizon

Top Research Reports for Johnson & Johnson, Visa & Verizon

GOOGL : 1,193.89 (+1.21%)
MO : 60.71 (-0.57%)
VZ : 53.05 (-0.92%)
V : 149.58 (+0.32%)
JNJ : 138.64 (-1.30%)
NKE : 84.79 (+0.62%)
Evaluate Ltd: Worldwide medtech Sales Forecast to Reach $595 Billion by 2024, with a CAGR of 5.6%, Anchored by Familiar Players

The global medtech industry is forecast to grow at a CAGR of 5.6% from 2017 to 2024 and reach $595 billion in sales by 2024, according to the latest report from Evaluate Ltd. Medtronic was...

ABT : 72.20 (+1.06%)
MHMNF : 54.5000 (unch)
JNJ : 138.64 (-1.30%)
MDT : 99.00 (+0.14%)
Consumer-Driven Attention Marketplace Dabbl on Track to Exceed 35 Million Brand Engagements in Less Than a Year, Proving Direct Consumer Relationships Are Scalable for Brands

Dabbl,a trustworthy attention marketplace for consumers and brands, showed considerable growth through the first half of 2018, with rapid user growth, early adoption among many top brands,...

JNJ : 138.64 (-1.30%)
Bull of the Day: Penumbra (PEN)

Bull of the Day: Penumbra (PEN)

AXGN : 37.50 (+2.32%)
EW : 168.35 (+1.74%)
ABT : 72.20 (+1.06%)
SYK : 175.77 (-0.18%)
MZOR : 58.20 (-0.03%)
JNJ : 138.64 (-1.30%)
PEN : 155.65 (+2.47%)
IART : 64.73 (+1.65%)
BAX : 77.46 (-0.37%)
MDT : 99.00 (+0.14%)
Bull of the Day: Penumbra (PEN)

Bull of the Day: Penumbra (PEN)

AXGN : 37.50 (+2.32%)
EW : 168.35 (+1.74%)
ABT : 72.20 (+1.06%)
SYK : 175.77 (-0.18%)
MZOR : 58.20 (-0.03%)
JNJ : 138.64 (-1.30%)
PEN : 155.65 (+2.47%)
IART : 64.73 (+1.65%)
BAX : 77.46 (-0.37%)
MDT : 99.00 (+0.14%)
J&J's Esketamine Fails to Meet Endpoint in Phase III Study

J&J's (JNJ) late-stage candidate, esketamine nasal spray, fails to show statistical significance for the primary endpoint in a phase III study on patients with treatment-resistant depression.

JNJ : 138.64 (-1.30%)
LLY : 105.70 (+0.10%)
RHHBY : 30.5500 (+1.26%)
BMY : 61.82 (+0.37%)
AstraZeneca's Diabetes Treatment Reduces Cardiovascular Risk

AstraZeneca's (AZN) Farxiga led to a statistical significant reduction in hospitalization for heart failure or CV death in a cardiovascular outcomes study.

AZN : 38.69 (+2.22%)
JNJ : 138.64 (-1.30%)
LLY : 105.70 (+0.10%)
BMY : 61.82 (+0.37%)
Global Antihistamines Market to 2026 - Key Players are Bayer, Almirall, Johnson & Johnson, AstraZeneca, Novartis, Pfizer, Sanofi, Boehringer Ingelheim, Merck & Co, Akorn & Teva

https://mma.prnewswire.com/media/732750/Research_and_Markets.jpg

JNJ : 138.64 (-1.30%)
MRK : 70.65 (-0.18%)
Evarrest (Johnson & Johnson) 2017-2018 U.S. Promotional Audit Report - ResearchAndMarkets.com

The "Evarrest 2017 U.S. Promotional Audit Report" report has been added to ResearchAndMarkets.com's offering.

JNJ : 138.64 (-1.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade JNJ with:

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 141.89
1st Resistance Point 140.27
Last Price 138.64
1st Support Level 137.71
2nd Support Level 136.77

See More

52-Week High 148.32
Last Price 138.64
Fibonacci 61.8% 136.97
Fibonacci 50% 133.47
Fibonacci 38.2% 129.97
52-Week Low 118.62

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar